Triple threat: new vaccine aims to tackle three salmonella strains at once
NCT ID NCT05784701
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests a new vaccine designed to protect against three common types of Salmonella bacteria that cause serious infections in Sub-Saharan Africa. The trial includes healthy participants ranging from adults down to young infants, and compares the vaccine to a placebo to see if it is safe and triggers a strong immune response. Researchers are also testing different doses and a booster schedule to find the best way to use the vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trivalent Salmonella conjugate vaccine (TSCV)
- What this could lead to
- If successful, this vaccine could help protect against three major types of Salmonella infections, reducing severe illness and death in regions where these diseases are common.
- What could go wrong
- This is a Phase 2 trial, so the vaccine is still being tested for safety and immune response. It may not provide enough protection or could cause side effects, and larger studies are needed before it can be widely used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIVALENT SALMONELLA CONJUGATE VACCINE (TSCV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Vaccine Development (CVD-Mali)
Bamako, Mali